Analysis Tools
mortality/aging
 |
• mice exhibit convulsions and death at a dose of MK212 (a HTR2C-selective agonist) that is 100 times lower than in wild-type mice
|
|
|
• less than 20% of mice survive the postnatal period
• however, removal of competing wild-type and female heterozygous littermates increases survival to 80%
|
homeostasis/metabolism
|
N |
• despite decreased growth, mice exhibit normal levels of thyroxine and corticosterone
|
|
|
• at 3 weeks but not 6 weeks
|
|
|
• at 3 weeks, circulating ghrelin levels are higher than in wild-type mice
• however, by 6 weeks circulating ghrelin levels are normal
|
|
|
• at 3 and 6 weeks
|
|
|
• at 3 weeks, circulating leptin levels are lower than in wild-type mice
• however, leptin levels are normal at 6 weeks
|
|
|
• mice exhibit more prominent hypothermia than wild-type mice in response to 8-OH-DPAT (a HTR1A-specific agonist)
• however, untreated mice exhibit normal body temperature
|
|
|
• unlike in wild-type mice, metabolic rate is not increased by treatment with CL316243 (a beta-adrenergic-specific agonist)
|
|
|
• mice exhibit a 40% increase in basal metabolic rate compared to in wild-type mice
• treatment with SB242084 reduces energy expenditure but it remains higher than in wild-type mice
|
|
|
• mice exhibit convulsions and death at a dose of MK212 (a HTR2C-selective agonist) that is 100 times lower than in wild-type mice
|
|
|
• mice exhibit more prominent hypothermia than wild-type mice in response to 8-OH-DPAT (a HTR1A-specific agonist)
• mice exhibit convulsions and death at a dose of MK212 (a HTR2C-selective agonist) that is 100 times lower than in wild-type mice
• mice exhibit increased sensitivity to mCPP and Ro60-0174, HTR2C-selective agonists
|
growth/size/body
|
|
• adipose accumulation is lower than in wild-type mice
|
|
|
• mice exhibit decreased body length compared to wild-type mice but this difference becomes less significant after weaning
|
|
|
• postnatal growth retardation is not rescued by injection of growth hormone
|
|
|
• despite normal birth weights, mice exhibit a 50% reduction in body weight gain compared to wild-type mice regardless of strain background or fostering with wild-type mothers
• however, between 3 and 5 weeks of age growth rates are normal
|
behavior/neurological
|
|
• low doses of MK212 result in more pronounced hypoactivity than in wild-type mice, and food intake can be decreased by treatment with MK212 or mCPP
• low doses of SB242084, but not ketanserin or SB204741 (all HTR2C-specific antagonists) induce more hypolocomotion than in wild-type mice that cannot be reverted by treatment with haloperidol (a D2, D3 and D4 dopamine receptor antagonist) or R(+)-SCH23390 (a D1 dopamine receptor antagonist)
|
polyphagia
(
J:142503
)
|
|
• mice exhibit hyperphagia
• however, food intake can be decreased by treatment with MK212
|
|
|
• mice are 2-fold less active than wild-type mice
|
adipose tissue
|
|
• adipose accumulation is lower than in wild-type mice
|
